|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer显示文摘Objective:Response Evaluation Criteria in Solid Tumors(RECIST)guideline version 1.0(RECIST 1.0)was proposed as a new guideline for evaluating tumor response and has been widely accepted as a standardized measure.With a number of issues being raised on RECIST 1.0,however,a revised RECIST guideline version 1.1(RECIST 1.1)was proposed by the RECIST Working Group in 2009.This study was conducted to compare CT tumor response based on RECIST 1.1 vs.RECIST 1.0 in patients with advanced gastric cancer(AGC).Methods:We reviewed 61 AGC patients with measurable diseases by RECIST 1.0 who were enrolled in other clinical trials between 2008 and 2010.These patients were retrospectively re-analyzed to determine the concordance between the two response criteria using theκstatistic.Results:The number and sum of tumor diameters of the target lesions by RECIST 1.1 were significantly lower than those by RECIST 1.0(P<0.0001).However,there was excellent agreement in tumor response between RECIST 1.1 and RECIST 1.0(κ=0.844).The overall response rates(ORRs)according to RECIST1.0 and RECIST 1.1 were 32.7%(20/61)and 34.5%(20/58),respectively.One patient with partial response(PR)based on RECIST 1.0 was reclassified as stable disease(SD)by RECIST 1.1.Of two patients with SD by RECIST 1.0,one was downgraded to progressive disease and the other was upgraded to PR by RECIST 1.1.Conclusions:RECIST 1.1 provided almost perfect agreement with RECIST 1.0 in the CT assessment of tumor response of AGC. | Gil-Su Jang Min-Jeong Kim Hong-Il Ha Jung Han Kim Hyeong Su Kim Sung Bae Ju Dae Young Zang | 2013 | Chinese Journal of Cancer Research2013，25，6： | 42 |
| 2 | Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice显示文摘瞄准:增加的证据建议那 probucol,有抗氧化剂活动的一个类脂化合物阴沉的代理人,可能为有经由在胆固醇和 neuroinflammation 的减小的 hyperlipidemia 的 ischemic 击的治疗有用。在这研究,我们检验了 probucol 是否能在正常和 hyperlipidemic mice.Methods 经由 anti-neuroinflammatory 行动免于大脑 ischemic 损害:主要老鼠 microglia 和鼠科的 BV2 microglia 不为 3 h,和版本暴露于 lipopolysaccharide (LPS ) , PGE2, IL-1β并且在 NF-κ 的 IL-6,以及变化; B,表明小径的 MAPK 和 AP-1 被估计。ApoE 击倒老鼠被喂包含 0.004% 的一本高脂肪的食谱, 0.02% , 0.1%(wt/wt ) 为 10 个星期的 probucol 而正常 C57BL/6J 老鼠收到了 probucol (3, 10, 30 mg· kg -1·d-1, po ) 为 4 d。然后,所有老鼠通过中间的服的动脉吸藏(MCAO ) 受到焦点的服的局部缺血。神经病学的赤字被获得在外科以后的 24 h,然后大脑为测量服的梗塞尺寸和支持 inflammatory mediators.Results 的生产被移开:在对待 LPS 的 BV2 房间和主要 microglial 房间,有 probucol 的预告的处理(1, 5, 10 μ mol/L ) dose-dependently 禁止了版本没有, PGE2, IL-1β并且 IL-6,它发生在抄写铺平。而且, probucol 的禁止的行动与 NF-κ 的 downregulation 被联系;表明小径的 B, MAPK 和 AP-1。在有 MCAO 的正常鼠标, probucol 的管理前 dose-dependently 减少了梗塞卷和改进神经病学的功能。这些效果被支持 inflammatory 调停人的减少的生产伴随(iNOS, COX-2, IL-1, IL-6 ) 。在 ApoE 击倒,老鼠喂了一本高脂肪的食谱, 0.1% probucol 的管理前显著地减少了梗塞体积,改进了跟随 MCAO 的神经病学的赤字,并且减少全部胆固醇并且 LDL 胆固醇 levels.Conclusion:Probucol 禁止导致 LPS 的 microglia 激活并且改善在经由它的 anti-neuroinflammatory 行动的正常和 hyperlipidemic 老鼠的服的 ischemic 损害,建议那 probucol 为 ischemic 击和 hyperlipidemia 为病人的治疗有潜力与或在风险。 | Yeon Suk JUNG Jung Hwa PARK Hyunha KIM So Young KIM Ji Young HWANG Ki Whan HONG Sun Sik BAE Byung Tae CHOI Sae-Won LEE Hwa Kyoung SHIN | 2016 | Acta Pharmacologica Sinica2016，37，8： | 16 |
| 3 | Gastric cancer patients at high-risk of having synchronous cancer显示文摘瞄准:识别病人与一在胃的癌症病人之中有同步癌症高风险。方法:我们回顾地在国家癌症中心分析了未来的胃的癌症数据库,从 2000 年 12 月的朝鲜到 2004 年 12 月。有没有同步癌症的病人的同步癌症和那些的病人的 clinicopathological 特征被比较。Multivariate 分析被执行在胃的癌症病人为同步癌症的存在识别风险因素。结果:在数据库登记的 3291 个胃的癌症病人(3.4%) 中的 111 个有同步癌症。在这 111 个病人之中, 109 有单个同步癌症, 2 个病人有二同步癌症。同步癌症的最普通的形式是颜色表面的癌症(42 个病人, 37.2%) 由肺癌症列在后面(21 个病人, 18.6%) 。Multivariate 分析表明有区分的早胃的癌症的老病人有同步癌症的更高的可能性。结论:在胃的癌症病人的同步癌症不是很少发生的。医生应该试着在胃的癌症病人发现同步癌症,在特别与区分的早胃的癌症老。 | Jun Ho Lee Ja Seong Bae Keun Won Ryu Jong Seok Lee Sook Ryun Park Chan Gyoo Kim Myoung Cheorl Kook Il Ju Choi Young Woo Kim Jae-Gahb Park Jae-Moon Bae | 2006 | World Journal of Gastroenterology2006，12，16： | 15 |
| 4 | Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis显示文摘AIM To evaluate the safety and efficacy of tenofovir disoproxil fumarate(TDF) as a first-line therapy in decompensated liver disease. METHODS We enrolled 174 chronic hepatitis B-related liver cirrhosis patients treated with 300 mg/d TDF at six Korean centers. Of the 174 cirrhosis patients, 57 were assigned to the decompensated cirrhosis group and 117 were assigned to the compensated cirrhosis group. We followed the patients for 12 mo and evaluated clinical outcomes, including biochemical, virological, and serological responses. We also evaluated changes in hepatic and renal function and compared the decompensated and compensated cirrhosis groups. RESULTS The 1-year complete virological response(CVR) and Hepatitis B e antigen(HBe Ag) seroconversion were seen in 70.2% and 14.2% in the decompensated cirrhosis group, respectively. The rates of HBe Ag seroconversion/loss and ALT normalization at month 12 were similar in both groups. TDF treatment was also effective for decreasing the level of hepatitis B virus(HBV) DNA in both groups, but CVR was higher in the compensated group(88.9% vs 70.2%, P = 0.005). Tenofovir treatment for 12 mo resulted in improved Child-Turcotte-Pugh(CTP) and model for end-stage liver disease(MELD) scores in decompensated group(P < 0.001). Of the 57 decompensated patients, 39(68.4%) achieved CTP class A and 27(49.1%) showed improvement in the CTP score of 2 points after 12 mo of TDF. The observed rate of confirmed 0.5 mg/d L increases in serum levels of creatinine in the decompensated and compensated cirrhosis group were 7.0% and 2.5%, respectively(P < 1.000).CONCLUSION TDF therapy in decompensated cirrhosis patients was effective for decreasing HBV DNA levels and improving hepatic function with relatively lower CVR than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients. | Soon Kyu Lee Myeong Jun Song Seok Hyun Kim Byung Seok Lee Tae Hee Lee Young Woo Kang Suk Bae Kim Il Han Song Hee Bok Chae Soon Young Ko Jae Dong Lee | 2017 | World Journal of Gastroenterology2017，23，13： | 14 |
| 5 | Association of chronic viral hepatitis B with insulin resistance显示文摘AIM:To investigate the relationship between chronic viral hepatitis B(CVHB) and insulin resistance(IR) in Korean adults.METHODS:A total of 7880 adults(3851 men,4029 women) who underwent a comprehensive medical examination were enrolled in this study.Subjects diagnosed with either diabetes mellitus,or any other disorder that could influence their insulin sensitivity,were rejected.Anthropometry,metabolic risk factors,hepatitis B surface antigen,hepatitis B surface antibody,hepatitis B core antibody,fasting plasma glucose and insulin were measured for all subjects.Homeostasis model assessment(HOMA),quantitative insulin check index(QUICKI),and Mf fm index were used for determining insulin sensitivity.Each participant was categorized into a negative,recovery,or CVHB group.To compare variables between groups,a t-test and/or one-way analysis of variance were used.Partial correlation coefficients were computed to present the association between insulin resistance and other variables.Multiple logistic regression analysis was used to assess the independent association between CVHB and IR.RESULTS:The mean age of men and women were 48.9 and 48.6 years,respectively.Subjects in the CVHB group had significantly higher waist circumference [(86.0 ± 7.7 cm vs 87.3 ± 7.8 cm,P = 0.004 in men),(78.3 ± 8.6 cm vs 80.5 ± 8.5 cm,P < 0.001 in women)],cystatin C [(0.96 ± 0.15 mg/dL vs 1.02 ± 0.22 mg/dL,P < 0.001 in men),(0.84 ± 0.15 mg/dL vs 0.90 ± 0.16 mg/dL,P < 0.001 in women)],fasting insulin [(5.47 ± 3.38 U/mL vs 6.12 ± 4.62 U/mL,P < 0.001 in men),(4.57 ± 2.82 U/mL vs 5.06 ± 3.10 U/mL,P < 0.001 in women)] and HOMA index [(1.24 ± 0.86 vs 1.43 ± 1.24,P < 0.001 in men),(1.02 ± 0.76 vs 1.13 ± 0.87,P = 0.033 in women)] compared to control group.The HOMA index revealed a positive correlation with body mass index(BMI)(r = 0.378,P < 0.001),waist circumference(r =0.356,P < 0.001),percent body fat(r = 0.296,P < 0.001),systolic blood pressure(r = 0.202,P < 0.001),total cholesterol(r = 0.134,P < 0.001),triglycerides(r = 0.292,P < 0.001),cystatin C(r = 0.069,P < 0.001) and uric acid(r = 0.142,P < 0.001).The QUICKI index revealed a negative correlation with BMI(r =-0.254,P < 0.001),waist circumference(r = 0-0.243,P < 0.001),percent body fat(r =-0.217,P < 0.001),systolic blood pressure(r =-0.132,P < 0.001),total cholesterol(r =-0.106,P < 0.001),triglycerides(r =-0.205,P < 0.001),cystatin C(r =-0.044,P < 0.001) and uric acid(r =-0.096,P < 0.001).For subjects identified with IR,the odds ratio of an accompanying diagnosis of chronic hepatitis B was 1.534(95% CI:1.158-2.031,HOMA index criteria) or 1.566(95% CI:1.124-2.182,QUICKI criteria) after adjustment for age,gender,BMI,and amount of alcohol consumption.CONCLUSION:Our study demonstrates that CVHB is associated with IR.CVHB may need to be monitored for occurrence of IR and diabetes mellitus. | Jeong Gyu Lee Sangyeoup Lee Yun Jin Kim Byung Mann Cho Joo Sung Park Hyung Hoi Kim JaeHun Cheong Dong Wook Jeong Yu Hyun Lee Young Hye Cho Mi Jin Bae Eun Jung Choi | 2012 | World Journal of Gastroenterology2012，18，42： | 10 |
| 6 | Family history influences the early onset of hepatocellular carcinoma显示文摘AIM: To evaluate the relationship between a positive family history of primary liver cancer and hepatocellular carcinoma (HCC) development in Korean HCC patients. METHODS: We studied a total of 2242 patients diagnosed with HCC between January 1990 and July 2008, whose family history of primary liver cancer was clearly described in the medical records.positive family history of HCC and 2077 (92.6%) did not. The male to female ratio was 3.6:1, and the major causes of HCC were chronic hepatitis B virus (HBV) infection in 75.1%, chronic hepatitis C virus infection in 13.2% and alcohol in 3.1%. The median ages at diag- nosis in the positiveand negative-history groups were 52 years (range: 29-79 years) and 57 years (range: 18-89 years), respectively (P < 0.0001). Furthermore, among 1713 HCC patients with HBV infection, the number of patients under 45 years of age out of 136 patients with positive family history was 26 (19.1%), whereas those out of 1577 patients with negative family history was 197 (12.5%), suggesting that a positive family history may be associated with earlier development of HCC in the Korean population (P = 0.0028). CONCLUSION: More intensive surveillance maybe recommended to those with a positive family history of HCC for earlier diagnosis and proper management especially when HBV infection is present. | Chung-Hwa Park Seung-Hee Jeong Hyeon-Woo Yim Jin Dong Kim Si Hyun Bae Jong Young Choi Seung Kew Yoon | 2012 | World Journal of Gastroenterology2012，18，21： | 9 |
| 7 | Gastric dysplasia may be an independent risk factor of an advanced colorectal neoplasm显示文摘AIM: To evaluate the relationship between gastric dysplasia and Helicobacter pylori (H pylori) and the occurrence of colorectal adenoma, and to defi ne the necessity for colonoscopy in patients with gastric dysplasia or H pylori infection.METHODS: From May 2005 to February 2008, 133 patients with established gastric dysplasia by gastroduo-denoscopy (EGD) were additionally investigated by colonoscopy. The authors compared results with those of 213 subjects who underwent both EGD and colonoscopy during the same period at the author’s Health Promotion Center as a control group. H pylori infection was evaluated in both the gastric dysplasia and control groups.RESULTS: The mean age of all 346 study subjects was 54.1 ± 10.5 years, and there were 258 (73%) men and 87 (27%) women. No signif icant difference was found between the H pylori positive and negative subjects in terms of the prevalence of colorectal adenoma and advanced colorectal adenoma (P = 0.261). Patients with gastric dysplasia showed no elevated risk of colorectal adenoma (OR = 0.910, 95% CI: 0.587-1.411, P = 0.738), but had a signif icantly higher risk of having advanced colorectal adenoma (OR = 3.382, 95% CI: 1.700-6.342, P = 0.000).CONCLUSION: The study emphasizes the need for colon surveillance in patients with gastric dysplasia, regardless of H pylori infection. | Rack Cheon Bae Seong Woo Jeon Han Jin Cho Min Kyu Jung Young Oh Kweon Sung Kook Kim | 2009 | World Journal of Gastroenterology2009，15，45： | 8 |
| 8 | Primary large cell neuroendocrine carcinoma in the common bile duct:First Asian case report显示文摘Large cell neuroendocrine carcinoma(LCNEC)in the biliary system is a poorly differentiated,high-grade neuroendocrine tumor.These tumors exhibit aggressive behavior and an increased tendency for early nodal and distant metastases.Herein,we report an unusual case of a pure primary LCNEC of the common bile duct(CBD).A 75-year-old female presented with nausea and jaundice.The patient underwent a CBD excision with lymph node dissection.Upon histological and immunohistochemical examination,the tumor exhibited pure large cell-type neuroendocrine features.Metastases were noted in two of the eight lymph nodes.The patient was administered adjuvant chemotherapy.The patient’s cancer recurred 7 mo after surgery,and the patient died from liver failure 5 mo after recurrence.The prognosis of LCNEC of CBD remains poor despitecurative resection and adjuvant chemotherapy.The role of additional therapies,such as multimodal treatment including radiation therapy,must be further studied to improve the prognoses of patients. | Sung Bae Park Suk Bae Moon Young Joon Ryu Jeana Hong Yang Hee Kim Gi Bong Chae Seong Kweon Hong | 2014 | World Journal of Gastroenterology2014，20，47： | 8 |
| 9 | Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B显示文摘AIM:To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment. METHODS:A total of 48 HBeAg positive chronic hepatitis B patients who were administered nucleoside analogues and maintained virological response for ≥ 6 mo [hepatitis B virus (HBV) DNA < 300 copies/mL and HBeAg seroconversion] before cessation of treatment were enrolled between February 2007 and January 2010. The criteria for the cessation of the antiviral treatment were defined as follows:(1) achievement of virological response; and (2) duration of consolidation therapy (≥ 6 mo). After treatment cessation, the patients were followed up at 3-6 mo intervals. The primary endpoint was serologic and virologic recurrence rates after withdrawal of antiviral treatment. Serologic recurrence was defined as reappearance of HBeAg positivity after HBeAg seroconversion. Virologic recurrence was defined as an increase in HBV-DNA level > 104 copies/mL after HBeAg seroconversion with previously undetectable HBV-DNA level. RESULTS:During the median follow-up period of 18.2 mo (range:5.1-47.5 mo) after cessation of antiviral treatment, the cumulative serological recurrence rate was 15 % at 12 mo. The median duration between the cessation of antiviral treatment and serologic recurrence was 7.2 mo (range:1.2-10.9 mo). Of the 48 patients with HBeAg positive chronic hepatitis, 20 (41.6%) showed virological recurrence. The cumulative virologic recurrence rates at 12 mo after discontinuing the antiviral agent were 41%. The median duration between off-treatment and virologic recurrence was 7.6 mo (range:4.3-27.1 mo). The mean age of the virological recurrence group was older than that of the non-recurrence group (46.7 ± 12.1 years vs 38.8 ± 12.7 years, respectively; P = 0.022). Age (> 40 years) and the duration of consolidation treatment (≥ 15 mo) were significant predictive factors for offtreatment durability in the multivariate analysis [P = 0.049, relative risk (RR) 0.31, 95% CI (0.096-0.998) and P = 0.005, RR 11.29, 95% CI (2.054-65.12), respectively]. Patients with age (≤ 40 years) who received consolidation treatment (≥ 15 mo) significantly showed durability in HBeAg positive chronic hepatitis B patients (P = 0.014). These results suggest that additional treatment for more than 15 mo after HBeAg seroconversion in patients who are ≤ 40 years old may be beneficial in providing a sustained virological response. CONCLUSION:Our data suggest that HBeAg seroconversion is an imperfect end point in antiviral treatment. Long-term consolidation treatment (≥ 15 mo) in younger patients is important for producing better prognosis in HBeAg positive chronic hepatitis B. | Myeong Jun Song Do Seon Song Hee Yeon Kim Sun Hong Yoo Si Hyun Bae Jong Young Choi Seung Kew Yoon Yong-Han Paik June Sung Lee Hyun Woong Lee Hyung Joon Kim | 2012 | World Journal of Gastroenterology2012，18，43： | 7 |
| 10 | Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma显示文摘AIM:To investigate the efficacy and safety of transarterial chemoembolization(TACE)-based multimodal treatment in patients with large hepatocellular carcinoma(HCC).METHODS:A total of 146 consecutive patients were included in the analysis,and their medical records and radiological data were reviewed retrospectively.RESULTS:In total,119 patients received TACE-based multi-modal treatments,and the remaining 27 received conservative management.Overall survival(P<0.001)and objective tumor response(P=0.003)were significantly better in the treatment group than in the conservative group.After subgroup analysis,survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group(P=0.002)but also in the surgical treatment group compared with the loco-regional treatment-only group(P<0.001).Multivariate analysis identified tumor stage(P<0.001)and tumor type(P=0.009)as two independent pre-treatment factors for survival.After adjusting for significant pre-treatment prognostic factors,objective response(P<0.001),surgical treatment(P=0.009),and multi-modal treatment(P=0.002)were identified as independent post-treatment prognostic factors.CONCLUSION:TACE-based multi-modal treatments were safe and more beneficial than conservative management.Salvage surgery after successful downstaging resultedin long-term survival in patients with large,unresectable HCC. | Do Seon Song Soon Woo Nam Si Hyun Bae Jin Dong Kim Jeong Won Jang Myeong Jun Song Sung Won Lee Hee Yeon Kim Young Joon Lee Ho Jong Chun Young Kyoung You Jong Young Choi Seung Kew Yoon | 2015 | World Journal of Gastroenterology2015，21，8： | 7 |
| 11 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis显示文摘AIM: To evaluate the prognostic factors and efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. METHODS: Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port. The epirubicin-cisplatin-5-fluorouracil (ECF) chemotherapeutic regimen consisted of 35 mg/m 2 epirubicin on day 1, 60 mg/m 2 cisplatin for 2 h on day 2, and 500 mg/m 2 5-fluorouracil for 5 h on days 1-3. The treatments were repeated every 3 or 4 wk. RESULTS: Three (6%) of the 50 patients achieved a complete response (CR), 13 (26%) showed partial responses (PR), and 22 (44%) had stable disease (SD).The median survival and time to progression were 7 and 2 mo, respectively. After 2 cycles of HAIC, CR was achieved in 1 patient (2%), PR in 10 patients (20%) and SD in 26 patients (52%). Significant pre-treatment prognostic factors were a tumor volume of < 400 cm 3 (P = 0.01) and normal levels of protein induced by vitamin K absence or antagonist (PIVKA)-Ⅱ (P = 0.022). After 2 cycles of treatment, disease control (CR + PR + SD) (P = 0.001), PVTT response (P = 0.003) and α-fetoprotein reduction of over 50% (P = 0.02) were independent factors for survival. Objective response (CR + PR), disease control, PVTT response, and combination therapy during the HAIC were also significant prognostic factors. Adverse events were tolerable and successfully managed. CONCLUSION: HAIC may be an effective treatment modality for advanced HCC with PVTT in patients with tumors < 400 cm 3 and good prognostic factors. | Do Seon Song Si Hyun Bae Myeong Jun Song Sung Won Lee Hee Yeon Kim Young Joon Lee Jung Suk Oh Ho Jong Chun Hae Giu Lee Jong Young Choi Seung Kew Yoon | 2013 | World Journal of Gastroenterology2013，19，29： | 5 |
| 12 | Anxiety and depression propensities in patients with acute toxic liver injury显示文摘AIM:To investigate anxiety and depression propensities in patients with toxic liver injury.METHODS:The subjects were divided into three groups:a healthy control group(Group 1,n=125),an acute non-toxic liver injury group(Group 2,n=124),and a group with acute toxic liver injury group caused by noncommercial herbal preparations(Group 3,n=126).These three groups were compared and evaluated through questionnaire surveys and using the Hospital Anxiety-Depression Scale(HADS),Beck Anxiety Inventory(BAI),Beck Depression Inventory(BDI),and the hypochondriasis scale.RESULTS:The HADS anxiety subscale was 4.9±2.7,5.0±3.0 and 5.6±3.4,in Groups 1,2,and 3,respectively.The HADS depression subscale in Group 3 showed the most significant score(5.2±3.2,6.4±3.4 and 7.2±3.4in Groups 1,2,and 3,respectively)(P<0.01 vs Group 1,P<0.05 vs Group 2).The BAI and BDI in Group 3showed the most significant score(7.0±6.3 and 6.9±6.9,9.5±8.6 and 8.8±7.3,10.7±7.2 and 11.6±8.5in Groups 1,2,and 3,respectively)(BAI:P<0.01 vs Group 1,P<0.05 vs Group 2)(BDI:P<0.01 vs Group1 and 2).Group 3 showed a significantly higher hypochondriasis score(8.2±6.0,11.6±7.5 and 13.1±6.5in Groups 1,2,and 3,respectively)(P<0.01 vs Group 1,P<0.05 vs Group 2).CONCLUSION:Psychological factors that present vulnerability to the temptation to use alternative medicines,such as herbs and plant preparations,are important for understanding toxic liver injury. | Jeong Ill Suh Jeong Kyu Sakong Kwan Lee Yong Kook Lee Jeong Bae Park Dong Joon Kim Yeon Seok SeoDepartment of Internal Medicine Korea University Anam Hospital Korea University College of Medicine Seoul 136-705 South Korea Jae Dong Lee Soon Young Ko Byung Seok Lee Seok Hyun Kim Byung Seok Kim Young Seok Kim Heon Ju Lee In Hee Kim Joo Hyun Sohn Tae Yeob Kim Byung Min Ahn | 2013 | World Journal of Gastroenterology2013，19，47： | 5 |
| 13 | Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation显示文摘AIM: To evaluate the risk factors for ischemic-type biliary lesion(ITBL) after ABO-incompatible(ABO-I) adult living donor liver transplantation(ALDLT).METHODS: Among 141 ALDLTs performed in our hospital between 2008 and 2014, 27(19%) were ABO-I ALDLT and 114 were ABO-identical/compatible ALDLT. In this study, we extensively analyzed the clinico-pathological data of the 27 ABO-I recipients to determine the risk factors for ITBL after ABO-I ALDLT. All ABO-I ALDLT recipients underwent an identical B-cell depletion protocol with preoperative rituximab, plasma exchange(PE), and operative splenectomy. The median follow-up period after transplantation was 26 mo. The clinical outcomes of the 27 ABO-I ALDLT recipients were compared with those of 114 ABO-identical/compatible ALDLT recipients.RESULTS: ITBL occurred in four recipients(14.8%) between 45 and 112 d after ABO-I ALDLT. The overall survival rates were not different between ABO-I ALDLT and ABO-identical/compatible ALDLT(P = 0.303). Among the ABO-I ALDLT recipients, there was no difference between patients with ITBL and those without ITBL in terms of B-cell and T-cell count, serum isoagglutinin titers, number of PEs, operative time and transfusion, use of graft infusion therapy, or number of remnant B-cell follicles and plasma cells in the spleen. However, the perioperative NK cell counts in the blood of patients with ITBL were significantly higher than those in the patients without ITBL(P < 0.05). Preoperative NK cell count > 150/μL and postoperative NK cell count > 120/μL were associated with greater relative risks(RR) for development of ITBL(RR = 20 and 14.3, respectively, P < 0.05). CONCLUSION: High NK cell counts in a transplant recipient's blood are associated with ITBL after ABO-I ALDLT. Further research is needed to elucidate the molecular mechanism of NK cell involvement in the development of ITBL. | Jun Bae Bang Bong-Wan Kim Young Bae Kim Hee-Jung Wang Hyun Yeong Lee Joohyun Sim Taegyu Kim Kyeong Lok Lee Xu-Guang Hu Wei Mao | 2016 | World Journal of Gastroenterology2016，22，30： | 5 |
| 14 | Improved Quality of Life Outcomes After Laparoscopy-Assisted Distal Gastrectomy for Early Gastric Cancer: Results of a Prospective Randomized Clinical Trial显示文摘 | Young-Woo Kim Yong Hae Baik Young Ho Yun Byung Ho Nam Dae Hyun Kim Il Ju Choi Jae-Moon Bae | 2008 | Annals of Surgery2008，，5： | 5 |
| 15 | Incremental age-related one-year MACCE after acute myocardial infarction in the drug-eluting stent era (from KAMIR-NIH registry)显示文摘ObjectivesTo 评估年龄相关的一个年专业在在尖锐心肌的梗塞(AMI ) 的经皮的冠的干预(一种总线标准) 以后的不利 cardiocerebrovascular 事件(MACCE ) 。我们从在 2011 年 11 月之间的健康(KAMIR-NIH ) 的朝鲜尖锐心肌的梗塞登记公民 Institue 在 13,104 个 AMI 病人全部的 AMI.MethodsA 以后分析了在年龄和一个年 MACCE 之间的协会, 2015 年 12 月根据年龄被分类进四个组(组我, < 60 年, n = 4199;组 II, 60-70 年, n = 2577;组织 III;70-80 年, n = 2774;组 IV, 80 年, n = 1018 ) 。病人们为 MACCE 合成的一个年被分析(心脏的死亡,心肌的梗塞,目标容器 revascularization,脑血管的事件) 在 AMI.ResultsThe 一个年以后,在 AMI 的 MACCE 是 3.5%( 组我) , 6.3%( 组 II ) , 9.6%( 组 III ) 并且 17.6%( 组 IV ) 。在为使参数惊讶的调整以后,分析结果证明有 AMI 的病人有一个年 MACCE 的增长风险[组 II,调整危险比率(aHR )= 1.224, 95% CI:0.965-1.525, P = 0.096;组 III, aHR = 1.316, 95% CI:1.037-1.671, P = 0.024;组 IV, aHR = 1.975, 95% CI:1.500-62.601, P < 0.001 ) 与相比组我。特别,心脏的死亡在玩的主要结束点合成在这效果的一个主要角色(组 II, aHR = 1.335, 95% CI:0.941-1.895, P = 0.106;组 III, aHR = 1.575, 95% CI:1.122-2.210, P = 0.009;组 IV, aHR = 2.803, 95% CI:1.937-4.054, P < 0.001 ).ConclusionsDespite 在 AMI 为一种总线标准推进了技术和药,年龄仍然在临床的结果施加强大的影响。小心的途径,甚至在发达心病学的现代时代被需要为在 AMI 干预年老人口。 | Dae-Won Kim Sung-Ho Her Ha Wook Park Kiyuk Chang Wook Sung Chung Ki Bae Seung Myung Ho Jeong Hyo-Soo Kim Hyeon Cheoi Gwon In Whan Seong Kyung Kuk Hwang Shung Chull Chae Kwon-Bae Kim Young Jo Kim Kwang Soo Cha Seok Kyu Oh Jei Keon Chae Ji-Hoon Jung | 2018 | Journal of Geriatric Cardiology2018，15，9： | 4 |
| 16 | Mitochondria-targeting self-assembled nanoparticles derived from triphenylphosphonium-conjugated cyanostilbene enable site-specific imaging and anticancer drug delivery显示文摘为指向的同时的肿瘤的 Subcellular 细胞器特定的 nanoparticles,成像,和药交货具有对癌症治疗的庞大的兴趣。此处,我们报导一根选择指向线粒体的探针 1,它被与 cyanostilbene 和长烷基链一半合并 triphenyl 磷化氢综合。探查 1 被发现经由导致聚集的排放(AIE ) 显示荧光。低分子重量的基于 cyanostilbene 的探查有或没有 anticancer 药, 1 与 ca 形成了狭窄的同类的 nanorod。有 ca 的长度或 nanoparticles 的 110 nm。在水的媒介的 20 nm 直径。自我装配的 cyanostilbene nanoparticles (N1 ) 有选择地在癌症房间的线粒体积累了并且射出荧光。N1 也能交付 anticancer 药, doxorubicin (纪录影片) ,到有高效率的线粒体。更重要地, N1 在正常房间上为癌症房间展出了高度选择的 cytotoxicity。到生物系统的这自我装配的 nanoparticle 的大潜在的应用程序源于它在线粒体聚集的能力。这聚集在癌症房间在 mitochondrial 膜潜力在细胞内部的反应的氧种类并且到减少的产生导致了重要增加。而且,在老鼠的肿瘤织物举起实验建议自我装配的 N1 有能力使内在化并且有效地交付 anticancer 药进肿瘤纸巾。而且, N1 和包含 N1 的 doxorubicin (N1 纪录影片) 有效地在 vivo 在一个异种皮移植模型压制了肿瘤生长。一起拿,我们的调查结果显示 N1 的应用程序为潜在的指导图象的治疗以及一个地点特定的交货系统作为指向探查,药交货平台,和化学疗法的代理人的 mitochondrial 提供唯一的策略给癌症房间。 | Ka Young Kim Hanyong Jin Jaehyeon Park Sung Ho Jung Ji Ha Lee Hyesong Park Sung Kuk Kim Jeehyeon Bae Jong Hwa Jung | 2018 | Nano Research2018，11，2： | 4 |
| 17 | High-performance oxygen reduction and evolution carbon catalysis: From mechanistic studies to device integration显示文摘能容易集成于存在的高效、便宜的氧减小和进化催化剂的发展设备为利用 O 2-H2 O 化学,例如再生燃料房间和金属空气电池。此处,我们报导 NH 3-activated 做 N 的层次碳(NHC ) 催化剂经由一条可伸缩的线路综合了,并且表明它的设备集成。NHC 催化剂为氧减小反应(ORR ) 和氧进化反应(OER ) 展出了好性能,当综合时,借助于电气化学的研究和评估示威了进一个再生燃料房间的氧电极。为 ORR 和 OER 观察的活动比得上最先进的磅和红外催化剂在碱的环境完成的那些。我们进一步通过密度为电气化学的活动作为活跃地点识别了碳缺点的关键角色功能的理论计算和高分辨率的 TEM 可视化。这个工作加亮 NHC 的潜力在再生燃料房间并且可能代替商业宝贵金属为断断续续的可更新的精力的划算的存储的金属空气电池。 | John W. F. To Jia Wei Desmond Ng Samira Siahrostami Ai Leen Koh Yangjin Lee Zhihua Chen Kara D. Fong Shucheng Chen Jiajun He Won-Gyu Bae Jennifer Wilcox Hu Young Jeong Kwanpyo Kim Felix Studt Jens K. Nфrskov Thomas F. Jaramillo Zhenan Bao | 2017 | Nano Research2017，10，4： | 4 |
| 18 | Risk factors of biliary intervention by imaging after livingdonor liver transplantation显示文摘AIM:To determine the risk factors of biliary intervention using magnetic resonance cholangiopancreatography(MRCP) after living donor liver transplantation(LDLT).METHODS: We retrospectively enrolled 196 patients who underwent right lobe LDLT between 2006 and 2010 at a single liver transplantation center. Direct duct-to-duct biliary anastomosis was performed in all 196 patients. MRCP images routinely taken 1 mo after LDLT were analyzed to identify risk factors for biliary intervention during follow-up, such as retrograde cholangiopancreatography or percutaneous transhepatic biliary drainage. Two experienced radiologists evaluated the MRCP findings, including the anastomosis site angle on three-dimensional images, the length of the filling defect on maximum intensity projection, bile duct dilatation, biliary stricture, and leakage.RESULTS: Eighty-nine patients underwent biliary intervention during follow-up. The anastomosis site angle [hazard ratio(HR) = 0.48; 95% confidence interval(CI), 0.30-0.75, P < 0.001], a filling defect in the anastomosis site(HR = 2.18, 95%CI: 1.41-3.38,P = 0.001), and biliary leakage(HR = 2.52, 95%CI: 1.02-6.20, P = 0.048) on MRCP were identified in the multivariate analysis as significant risk factors for biliary intervention during follow-up. Moreover, a narrower anastomosis site angle(i.e., below the median angle of 113.3°) was associated with earlier biliary intervention(38.5 ± 4.2 mo vs 62. 1 ± 4.1 mo, P < 0.001). Kaplan-Meier analysis comparing biliary intervention-free survival according to the anastomosis site angle revealed that lower survival was associated with a narrower anastomosis site angle(36.3% vs 62.0%, P < 0.001).CONCLUSION: The biliary anastomosis site angle in MRCP after LDLT may be associated with the need for biliary intervention. | Soon Kyu Lee Jong Young Choi Dong Myung Yeo Young Joon Lee Seung Kew Yoon Si Hyun Bae Jeong Won Jang Hee Yeon Kim Dong Goo Kim Young Kyoung You | 2016 | World Journal of Gastroenterology2016，22，7： | 4 |
| 19 | Expression of Ki-67,p53,and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma显示文摘AIM: To examine surgical specimens of pancreas with either chronic pancreatitis or pancreatic cancer in order to study whether ductal hyperplasia and dysplasia in pancreas represent precursor lesions for pancreatic cancer.METHODS: We examined expression of Ki-67, CEA,p53, and K-ras, in the surgical specimens of pancreas with adenocarcinomas (n = 11) and chronic pancreatitis (n = 12). Cellular proliferation was assessed by Ki-67proliferation index using the proliferation marker Ki-67.In specimens with pancreas cancer, we divided pancreas epithelium into normal (n=7), ductal hyperplasia (n=3), dysplasia (n=4), and cancerous lesion (n=11) after hematoxylin and eosin staining, Ki-67, and CEA immunohistochemical staining. In cases with chronic pancreatitis, the specimen was pathologically examined as in cases with pancreas cancer, and they were also determined as normal (n=10), ductal hyperplasia (n=4), or dysplasia (n= 5). p53 and K-ras expression were also studied by immunohistochemical staining.RESULTS: In pancreatic cancer, the Ki-67 index was 3.73±3.58 in normal site, 6.62±4.39 in ductalhyperplasia, 13.47±4.02 in dysplasia and 37.03±10.05in cancer tissue, respectively. Overall, p53 was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 14 (0%), 0 of 7 (0%), 7 of 9 (78%),and 10 of 11 (91%), respectively, and K-ras was positive in 0 of 8 (0%), 1 of 3 (33%), 4 of 6 (67%), 4 of 5 (80%),respectively.CONCLUSION: Our results favorably support the hypothesis that ductal hyperplasia and dysplasia of the pancreas might be precursor lesions for pancreas cancer.Further evaluation of oncogenes by the molecular study is needed. | Seok Jeong Don Haeng Lee Jung Il Lee Jin-Woo Lee Kye Sook Kwon Pum-Soo Kim Hyung Gil Kim Yong Woon Shin Young Soo Kim Young Bae Kim | 2005 | World Journal of Gastroenterology2005，11，43： | 4 |
| 20 | Akt is negatively regulated by the MULAN E3 ligase显示文摘serine/threonine kinase Akt 在多重细胞的进程工作,包括房间幸存和肿瘤开发。否定地调整 Akt 的机制的研究集中了于调停 dephosphorylation 的 inactivation。在这研究,我们识别了 Akt 的一个否定管理者, MULAN,它拥有一个戒指手指领域和 E3 ubiquitin ligase 活动。Akt 被发现直接与 MULAN 交往并且是由在 vitro 并且在 vivo 的 MULAN 的 ubiquitinated。另外的分子的试金证明 phosphorylated Akt 由 MULAN 是为和 MULAN 和 ubiquitination 的相互作用的一个真实目标。功能的研究的结果建议由 MULAN 的 Akt 的降级压制房间增长和生存能力。这些数据提供卓见进 Akt ubiquitination 发信号网络。 | Seunghee Bae Sun-Yong Kim Jin Hyuk Jung Yeongmin Yoon Hwa Jun Cha Hyunjin Lee Karam Kim Jongran Kim In-Sook An Jongdoo Kim Hong-Duck Um In-Chul Park Su-Jae Lee Seon Young Nam Young-Woo Jin Jae Ho Lee Sungkwan An | 2012 | Cell Research2012，22，5： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员